pteridines has been researched along with Blood Diseases in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data support further development of volasertib and a harmonised dosing for Asian and Caucasian patients." | 2.79 | A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. ( Cheng, AL; Fritsch, H; Hsu, CH; Huang, DC; Lin, CC; Lu, YS; Su, WC; Su, WP; Taube, T; Voss, F; Yang, JC; Yeh, KH; Yen, CJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, CC | 1 |
| Su, WC | 1 |
| Yen, CJ | 1 |
| Hsu, CH | 1 |
| Su, WP | 1 |
| Yeh, KH | 1 |
| Lu, YS | 1 |
| Cheng, AL | 1 |
| Huang, DC | 1 |
| Fritsch, H | 1 |
| Voss, F | 1 |
| Taube, T | 1 |
| Yang, JC | 1 |
1 trial available for pteridines and Blood Diseases
| Article | Year |
|---|---|
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Cell Cycle Proteins; Combined Modality Therapy; Dose-Response Re | 2014 |